Mendlein John's Form 4 filing
Fate Therapeutics IncFATE · filed Mar 11, 2022
- Accession no.
- 0001209191-22-018188
- Filed
- Mar 11, 2022
- Trade date
- Mar 10, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.11M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mendlein JohnCIK 0001238362 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2022 | Common Stock | MOption exerciseAcquired | +31,562 | $1.63 | +$51,446.06 | 191,017 | Direct | |
| Mar 10, 2022 | Common Stock | SSaleDisposed | −19,493 | $34.73F2 | −$676,991.89 | 171,524 | Direct | |
| Mar 10, 2022 | Common Stock | SSaleDisposed | −12,069 | $35.48F3 | −$428,208.12 | 159,455 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2022 | Common Stock | MOption exerciseDisposed | −31,562 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $34.12 to $35.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $35.13 to $35.75 per share.
Referenced by the price of 1 transaction in Table I.